Eledon Pharmaceuticals, Inc. (ELDN)

Over the past six months, Eledon Pharmaceuticals' stock experienced fluctuations due to clinical trial progress, financial updates, and market sentiment. The stock was downgraded to a hold-accumulate status in July 2025. Shares surged in September 2025 in anticipation of trial results. The company reported its Second Quarter 2025 Operating and Financial Results in August 2025 and its Third Quarter 2024 financial results in November 2024, which included a net income of $77.0 million. Eledon Pharmaceuticals is expected to report topline results from its Phase 2 BESTOW trial in kidney transplantation in the fourth quarter of 2025 and participated in several conferences.

Information regarding the specific demand seasonality for Eledon Pharmaceuticals, Inc.'s products and services is not publicly available through the current search capabilities.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, particularly through the CD40 Ligand (CD40L) pathway. Their lead product candidate, tegoprubart, is in clinical trials for preventing organ transplant rejection and treating autoimmune and neurodegenerative diseases.

Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California, USA, and plans to expand its operations globally.

In the past year, Eledon Pharmaceuticals' brand reputation has been positively influenced by advancements in its clinical programs and favorable analyst coverage. Cantor Fitzgerald reiterated an "Overweight" rating on the stock, and Stifel analysts adjusted their financial model, leading to improved forecasts. The company's lead candidate, tegoprubart, has shown promising early data in kidney transplant studies. Eledon also appointed Deloitte & Touche LLP as its new independent auditor.

Eledon Pharmaceuticals has a mixed ownership structure comprising institutional shareholders (approximately 51%), insiders, and retail investors (approximately 16%). Major institutional owners include BVF Partners L.P., RA Capital Management, L.P., The Vanguard Group Inc, and BlackRock, Inc. Seth Loring Harrison is the largest individual shareholder.